1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
MYUNGMOON Pharm co.,Ltd

MYUNGMOON Pharm co.,Ltd

017180.KS
MYUNGMOON Pharm co.,LtdKR flagKorea Exchange
1,221.00
KRW
-22.00
- -
40.82BMarket Cap
MYUNGMOON Pharm co.,Ltd
017180.KS
(Korea Exchange)

Recent

price

1,221.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
6,456.45
7,114.1
4,728.76
4,872.73
4,913.92
5,883.57
6,174.4
5,480.9
5,961.38
5,961.79
4,366.83
4,073.89
4,505.27
5,021.62
5,591.13
5,871.98
5,904.3
Revenue per Share
188.31
257.9
-577.27
48.2
35.49
-758.86
292.95
305.36
39.94
-814.44
-944
-203
233
-134
-91
57
90.5
Basic EPS, GAAP
-131.99
-263.14
-41.32
-127.89
-135.8
-439.65
-167.77
-555.03
12.68
-682.25
-652.72
14.2
104.44
-241.99
-82.19
-256.7
-199.71
Free Cash Flow per Basic Share
24.57
23.6
22.22
- -
12.58
14.71
14.05
45.14
96.59
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2,151.73
3,297.94
2,158.32
2,210.51
1,677.86
806.87
1,097.23
1,252.36
1,018.68
71.52
-571.99
-680.14
841.09
681.36
526.03
600.06
572.36
Book Value per Share
3,752.83
4,069.5
2,938
2,954.83
3,002.36
3,001.94
4,034.75
3,911.32
3,688
3,161.26
3,074.32
2,532.18
2,811.79
2,620.48
3,076.62
3,127.29
3,080.11
Tangible Book Value per Share
16
18
21
21
21
21
23
26
25
25
29
34
34
34
33
33
33
Basic Weighted Avg Shares
105,183
125,620
100,539
103,723
105,421
125,101
142,180
140,138
147,499
149,346
127,853
137,760
152,135
169,567
186,443
195,247
197,371
Sales/Revenue/Turnover
8.69
8.72
-3.7
3.96
3.53
-1.97
7.07
5.33
3.35
-9.57
-22.65
-4.27
4.23
0.57
1.03
3.5
4.07
Operating Margin (%)
3,089
2,279
2,252
2,255
2,306
2,022
2,003
1,980
1,914
3,661
4,201
4,203
4,238
4,168
4,066
3,962
2,368
Depreciation Expense
3,068
4,554
-12,273
1,026
761
-16,135
6,746
7,807
988
-20,402
-27,639
-6,865
7,868
-4,525
-3,035
1,895
3,025
Net Income, GAAP
57.59
30.29
- -
81.65
106.26
- -
20.93
19.54
82.68
- -
- -
- -
- -
- -
- -
46.46
34.31
Effective Tax Rate (%)
2.92
3.63
-12.21
0.99
0.72
-12.9
4.74
5.57
0.67
-13.66
-21.62
-4.98
5.17
-2.67
-1.63
0.97
1.53
Profit Margin (%)
17,807
20,147
12,515
-8,940
-5,243
-20,181
1,348
-7,983
-16,385
-32,641
-44,743
-45,622
-40,115
-34,937
-12,330
-4,291
-5,220
Working Capital
30,140
21,325
20,350
102
1,922
620
186
3,093
9,473
24,814
7,702
5,956
7,304
13,044
35,329
43,134
42,863
LT Debt
67,126
83,132
72,869
73,197
73,152
67,120
94,680
101,719
93,064
80,196
90,775
85,874
95,267
88,755
103,123
104,457
103,403
Total Equity
2.86
4.89
- -
0.46
-0.14
- -
4.7
3.28
0.45
- -
- -
- -
- -
- -
- -
1.88
2.73
Return on Invested Capital (%)
5.05
6.65
- -
1.85
0.98
- -
8.36
7.96
1.75
- -
- -
- -
- -
- -
- -
4.33
5.88
Return on Capital (%)
9.1
9.76
-23.57
2.21
1.83
-60.71
31.8
27.26
3.45
-151.15
- -
- -
- -
-17.6
-14.97
10.11
17.42
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
54,601
55,499
54,879
LT Borrowings
41,095
42,646
42,448
LT Finance Leases
531
488
415
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
33
33
33
Market Capitalization
56,093
61,769
61,308

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
92,248
92,072
93,413
Cash, Cash Equivalents & STI
6,697
6,145
4,560
Accounts Receivable, Net
43,832
42,868
43,190
Inventories
37,587
38,724
41,241
Total Current Liabilities
94,689
96,363
98,633
Payables & Accruals
- -
- -
- -
ST Debt
54,601
55,499
54,879
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.55%
3.24%
1.29%
Free Cash Flow
-508.44%
69.02%
211.43%
Net Income, GAAP
-298.51%
-128.54%
-162.46%
Sales/Revenue/Turnover
4.86%
8.86%
4.72%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
44,231
46,081
46,983
49,148
186,443
2025
45,875
48,757
49,862
50,753
195,247
2026
47,999
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-37
-46
-24
- -
-91
2025
-58
102.7
-16.42
- -
57
2026
-23.98
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
BioGaia AB (publ) (BIOGY)
AcelRx Pharmaceuticals, Inc. (ACRX)
PT Tempo Scan Pacific Tbk (TSPC.JK)
MERCK Kommanditgesellschaft auf Aktien (MER.SW)
Adcock Ingram Holdings Limited (AIHLF)
Tilray Brands, Inc. (2HQ.DE)
Business
MYUNGMOON Pharm co.,Ltd engages in the research, development, manufacture, distribution, and sale of pharmaceutical products primarily in South Korea with international operations. Founded in 1983 and headquartered in Seoul, South Korea, the company produces a wide range of pharmaceutical products including ethical (ETC) drugs and over-the-counter (OTC) drugs. Its main product categories include anesthetic agents; digestive system drugs; rheumatoid arthritis remedies; central nervous system drugs; circulatory drugs; anti-depressant agents; anti-diabetic agents; antibiotics; hormone agents; narcotics; dermatology and urology drugs; muscle relaxants; anti-osteoporosis drugs; steroids; appetite suppressants; and carcinostatic substances. Its OTC portfolio comprises antinauseant agents; hepatics; immunologic agents; antidiarrheal agents; skin external preparations; antiallergic agents; muscle relaxants; cold remedies; parasiticides; health supplements; multiple vitamins; eye nutrition products; eye drops; and topical analgesics. The company manufactures medicines in diverse forms such as injections, tablets, capsules, aerosols, patches, solutions, and creams. It holds numerous product licenses exceeding 400 for specialized and general medicines. MYUNGMOON operates two factories certified under PIC/s GMP and opened a high-tech manufacturing facility in 2018. Recent developments include ongoing clinical trials and pipeline advances focused on treatments such as Midodrine Hydrochloride for orthostatic hypotension, with first approval granted in 2025. The company continues to expand its pharmaceutical innovations with new product launches and strategic research initiatives addressing various therapeutic areas. In addition to pharmaceuticals, MYUNGMOON also engages in ancillary business activities such as golf course operations. Its strategic focus combines manufacturing excellence, broad product offerings, and active research and development to maintain competitive positioning in the pharmaceutical industry at home and abroad. The company completed a merger with a wholly owned subsidiary in 2012, enhancing operational efficiencies. Overall, MYUNGMOON Pharm co.,Ltd represents a well-established and diversified pharmaceutical enterprise with a strong R&D pipeline, a comprehensive portfolio of prescription and OTC drugs, and a commitment to technology-driven manufacturing excellence.